Figure S6 from Mastermind Like Transcriptional Coactivator 3 (MAML3) Drives Neuroendocrine Tumor Progression
Year: 2023
Type: other
Abstract: Western blot for expression of FL and dEx1 MAML3 domain constructs and luciferase assay. Cells for these blots were transfected at the same time as cells used for the luciferase experiment and harvested on the day the luciferase assay was performed. A. Protein expression of FL MAML3 domain constructs: FLâ^†C772 contains amino acids (aa) 1-772, FLâ^†C364 aa 1-364, FLâ^†Q aa 1-364 and 772-1133, FLâ^†S aa 1-195 and 365-1133, FLâ^†Nâ^†S aa 1-155 and 365-1133. B. Protein expression of dEx1 MAML3 domain constructs: dEx1â^†C772 contains amino acids (aa) 156-772, dEx1â^†C364 aa 156-364, dEx1â^†Q aa156-364 and 772-1133, dEx1â^†S aa 156-195 and 365-1133, dEx1â^†Nâ^†S aa 365-1133. C. TCF/LEF promoter activation by MAML3 constructs in QGP-1 and BON-1. Diagrams of each MAML3 construct are shown to the left of their relative promoter activation. All MAML3 constructs were co-transfected with β-catenin. Cells transfected with β-catenin alone, or with neither MAML3 nor β-catenin are shown as controls, in addition to the negative control FOP vector for every combination. Experiments was done three separate times in triplicate.
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362626023